search
Back to results

PSMA/CD70 Bi-specific CAR-T Cell Therapy

Primary Purpose

Cancer Disease

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
bi-4SCAR PSMA/CD70 T cells
Sponsored by
Shenzhen Geno-Immune Medical Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cancer Disease focused on measuring CAR-T, cancer, CD70, PSMA

Eligibility Criteria

1 Year - 75 Years (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients with tumor cells have received standard first-line therapy and have been judged to be non-resectable, metastatic, progressive or recurrent.
  2. The expression status of CD70 or PSMA antigens in the tumor tissue will be determined for eligibility. Positive expression is defined by CD70 and PMSA antibody staining results based on immunohistochemistry or flow cytometry analyses.
  3. Body weight greater than or equal to 10 kg.
  4. Age: ≥1 year and ≤ 75 years of age at the time of enrollment.
  5. Life expectancy: at least 8 weeks.
  6. Prior Therapy:

    There is no limit to the number of prior treatment regimens. Any grade 3 or 4 non-hematologic toxicity of any previous therapy must be resolved to grade 2 or less.

  7. Participant must not have received hematopoietic growth factors for at least 1 week prior to mononuclear cells collection.
  8. At least 7 days must have elapsed since the completion of therapy with a biologic agent, selected targeted agent or a metronomic non-myelosuppressive regimen.
  9. At least 4 weeks must have elapsed since prior therapy that included a monoclonal antibody.
  10. At least 1 week since any radiation therapy at the time of study entry.
  11. Karnofsky/jansky score of 60% or greater.
  12. Cardiac function: Left ventricular ejection fraction greater than or equal to 40/55 percent.
  13. Pulse Ox greater than or equal to 90% on room air.
  14. Liver function: defined as alanine transaminase (ALT) <3x upper limit of normal (ULN), aspartate aminotransferase (AST) <3x ULN; serum bilirubin and alkaline phosphatase <2x ULN.
  15. Renal function: Patients must have serum creatinine less than 3 times upper limit of normal.
  16. Marrow function: White blood cell count ≥1000/ul, Absolute neutrophil count ≥500/ul, Absolute lymphocyte count ≥500/ul, Platelet count ≥25,000/ul (not achieved by transfusion).
  17. Patients with known bone marrow metastatic disease will be eligible for enrollment as long as they meet hematologic function criteria, and the marrow disease does not have hematologic toxicity.
  18. For all patients enrolled in this study, themselves or their parents or legal guardians must sign an informed consent and assent.

Exclusion Criteria:

  1. Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction, or greater than grade 2 hematologic toxicity.
  2. Untreatable central nervous system (CNS) metastasis: Patients with previous CNS tumor involvement that has been treated and is stable for at least 4 weeks following completion of therapy are eligible.
  3. Previous treatment with other genetically engineered CD70 or PSMA-specific CAR T cells.
  4. Active HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) infection or uncontrolled infection.
  5. Patients who require systemic corticosteroid or other immunosuppressive therapy.
  6. Evidence of tumor potentially causing airway obstruction.
  7. Inability to comply with protocol requirements.
  8. Insufficient CAR T cells availability.

Sites / Locations

  • Shenzhen Geno-immune Medical InstituteRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

bi-4SCAR-PSMA/CD70 T Cell Therapy for CD70 and/or PSMA positive cancer

Arm Description

Outcomes

Primary Outcome Measures

Number of patients with adverse events.
Determine the toxicity profile the bi-4SCAR PSMA/CD70 cells with Common Toxicity Criteria for Adverse Effects version 4.0

Secondary Outcome Measures

Tumor remission response evaluation
Objective complete response (CR) are assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
Tumor remission response evaluation
Objective partial response (PR)) are assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
The expansion of bi-4SCAR PSMA/CD70 T cells
Scale of CAR copies (for efficacy)
The persistence of bi-4SCAR PSMA/CD70 T cells
Scale of tumor burden (for efficacy)
Survival time of the patients
The overall survival (OS) time of the patients treated with the bi-4SCAR PSMA/CD70 T cells will be evaluated
Survival time of the patients
The progression free survival (PFS) time of the patients treated with the bi-4SCAR PSMA/CD70 T cells will be evaluated

Full Information

First Posted
June 21, 2022
Last Updated
June 25, 2022
Sponsor
Shenzhen Geno-Immune Medical Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT05437341
Brief Title
PSMA/CD70 Bi-specific CAR-T Cell Therapy
Official Title
PSMA/CD70 Bi-specific CAR-T Cells for Cancer Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 30, 2022 (Anticipated)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
June 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shenzhen Geno-Immune Medical Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to assess the feasibility, safety and efficacy of anti-PSMA/CD70 bi-specific CAR-T cell therapy in patients with CD70 and PSMA positive malignancies. Another goal of the study is to learn more about the function of the PSMA/CD70 bi-specific CAR-T cells and their persistency in patients.
Detailed Description
Patients with refractory and/or recurrent cancer have poor prognosis despite complex multimodal therapy; therefore, novel curative approaches are needed. The investigators attempt to use T cells genetically modified to express a 4th generation lentiviral anti-PSMA/CD70 bi-specific chimeric antigen receptor (bi-4SCAR-PSMA/CD70). The chimeric antigen receptor (CAR) molecules enable the T cells to recognize and kill tumor cells through the recognition of a surface antigen, CD70 or PSMA, which is expressed at high levels on tumor cells but not at significant levels on normal tissues. CD70 is a promising therapeutic target due to its restricted expression in normal tissues and overexpression in malignant tissues. Expression of CD70 was observed on multiple tumor types including kidney, breast, esophageal, liver, colon cancer, glioma, lymphoma as well as melanoma. In addition, it has been reported that anti-CD70 CAR T-cell therapy eliminated primary CD70-positive cells and had strong anti-tumor effects in preclinical animal models. The CD70 targeted CAR-T cells with binding moiety of CD70 specific scFv exhibit a higher affinity and antitumor effect against CD70+ tumor cells. Prostate-specific membrane antigen (PSMA) is expressed in normal prostate and upregulated in prostate tumor. However, PSMA is not restricted to prostate cancer and it is known that PSMA is enriched in the tumor stromal environment. Based on immunostaining, it is confirmed that PSMA is expressed in a variety of solid tumors, including brain tumor, neuroblastoma and some lymphomas. Therefore, PSMA is a promising target for immunotherapy of many types of cancer. A potential strategy to prevent relapse due to antigen escape is to infuse T-cells capable of recognizing multiple antigens. To overcome tumor escape of single target antigen and enhance in vivo CAR-T efficacy, a novel bi-specific PSMA/CD70 CAR-T therapy regimen is developed to include booster and consolidation CAR-T applications to target highly-refractory cancer. The aim is to evaluate safety and long term efficacy of the bi-CAR-T therapy strategy in CD70 and/or PSMA positive cancer patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer Disease
Keywords
CAR-T, cancer, CD70, PSMA

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
bi-4SCAR-PSMA/CD70 T Cell Therapy for CD70 and/or PSMA positive cancer
Arm Type
Experimental
Intervention Type
Biological
Intervention Name(s)
bi-4SCAR PSMA/CD70 T cells
Intervention Description
Infusion of bi-4SCAR PSMA/CD70 T cells at 10^6 cells/kg body weight via IV
Primary Outcome Measure Information:
Title
Number of patients with adverse events.
Description
Determine the toxicity profile the bi-4SCAR PSMA/CD70 cells with Common Toxicity Criteria for Adverse Effects version 4.0
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Tumor remission response evaluation
Description
Objective complete response (CR) are assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
Time Frame
1 year
Title
Tumor remission response evaluation
Description
Objective partial response (PR)) are assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
Time Frame
1 year
Title
The expansion of bi-4SCAR PSMA/CD70 T cells
Description
Scale of CAR copies (for efficacy)
Time Frame
1 year
Title
The persistence of bi-4SCAR PSMA/CD70 T cells
Description
Scale of tumor burden (for efficacy)
Time Frame
1 year
Title
Survival time of the patients
Description
The overall survival (OS) time of the patients treated with the bi-4SCAR PSMA/CD70 T cells will be evaluated
Time Frame
3 years
Title
Survival time of the patients
Description
The progression free survival (PFS) time of the patients treated with the bi-4SCAR PSMA/CD70 T cells will be evaluated
Time Frame
3 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with tumor cells have received standard first-line therapy and have been judged to be non-resectable, metastatic, progressive or recurrent. The expression status of CD70 or PSMA antigens in the tumor tissue will be determined for eligibility. Positive expression is defined by CD70 and PMSA antibody staining results based on immunohistochemistry or flow cytometry analyses. Body weight greater than or equal to 10 kg. Age: ≥1 year and ≤ 75 years of age at the time of enrollment. Life expectancy: at least 8 weeks. Prior Therapy: There is no limit to the number of prior treatment regimens. Any grade 3 or 4 non-hematologic toxicity of any previous therapy must be resolved to grade 2 or less. Participant must not have received hematopoietic growth factors for at least 1 week prior to mononuclear cells collection. At least 7 days must have elapsed since the completion of therapy with a biologic agent, selected targeted agent or a metronomic non-myelosuppressive regimen. At least 4 weeks must have elapsed since prior therapy that included a monoclonal antibody. At least 1 week since any radiation therapy at the time of study entry. Karnofsky/jansky score of 60% or greater. Cardiac function: Left ventricular ejection fraction greater than or equal to 40/55 percent. Pulse Ox greater than or equal to 90% on room air. Liver function: defined as alanine transaminase (ALT) <3x upper limit of normal (ULN), aspartate aminotransferase (AST) <3x ULN; serum bilirubin and alkaline phosphatase <2x ULN. Renal function: Patients must have serum creatinine less than 3 times upper limit of normal. Marrow function: White blood cell count ≥1000/ul, Absolute neutrophil count ≥500/ul, Absolute lymphocyte count ≥500/ul, Platelet count ≥25,000/ul (not achieved by transfusion). Patients with known bone marrow metastatic disease will be eligible for enrollment as long as they meet hematologic function criteria, and the marrow disease does not have hematologic toxicity. For all patients enrolled in this study, themselves or their parents or legal guardians must sign an informed consent and assent. Exclusion Criteria: Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction, or greater than grade 2 hematologic toxicity. Untreatable central nervous system (CNS) metastasis: Patients with previous CNS tumor involvement that has been treated and is stable for at least 4 weeks following completion of therapy are eligible. Previous treatment with other genetically engineered CD70 or PSMA-specific CAR T cells. Active HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) infection or uncontrolled infection. Patients who require systemic corticosteroid or other immunosuppressive therapy. Evidence of tumor potentially causing airway obstruction. Inability to comply with protocol requirements. Insufficient CAR T cells availability.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lung-Ji Chang, PhD
Phone
86-0755-86725195
Email
c@szgimi.org
Facility Information:
Facility Name
Shenzhen Geno-immune Medical Institute
City
Shenzhen
State/Province
Guangdong
ZIP/Postal Code
518000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lung-Ji Chang, PhD
Phone
86-075586725195
Email
c@szgimi.org

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

PSMA/CD70 Bi-specific CAR-T Cell Therapy

We'll reach out to this number within 24 hrs